GoodRx Holdings (GDRX)
NASDAQ:GDRX
Top Page
GoodRx Holdings
(NASDAQ:GDRX)
Select Model
Select Model
Rating:62Neutral
Price Target:
$2.00
▼(-10.31% Downside)
Action:ReiteratedDate:03/07/26
The score is driven primarily by improved financial stability (profitability rebound, consistent cash generation, and sharply reduced leverage), partially offset by weak price trends and a transitional earnings outlook where 2026 guidance points to revenue/EBITDA declines and continued pressure in the core prescription transactions business. Valuation is supportive but not strong enough to outweigh near-term growth and momentum risks.
Positive Factors
Strengthened balance sheet
Materially de‑risked balance sheet with sizable cash and undrawn credit enhances financial flexibility over the medium term. This allows the company to fund investments in growth initiatives, absorb partner headwinds, and reduces refinancing/liquidity risk while enabling disciplined capital returns.
Negative Factors
Declining core prescription transactions
Prescription transactions remain a material portion of revenue; persistent declines erode base cash flow and reduce resilience. Sustained weakness in this core market requires either margin recovery or accelerated success in new business lines to preserve long‑term profitability and cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthened balance sheet
Materially de‑risked balance sheet with sizable cash and undrawn credit enhances financial flexibility over the medium term. This allows the company to fund investments in growth initiatives, absorb partner headwinds, and reduces refinancing/liquidity risk while enabling disciplined capital returns.
Read all positive factors
GoodRx Holdings (GDRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$736.54M
Dividend YieldN/A
Average Volume (3M)2.34M
Price to Earnings (P/E)42.5
Beta (1Y)0.74
Revenue Growth1.30%
EPS GrowthN/A
CountryUS
Employees738
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.09
Shares Outstanding108,610,310
10 Day Avg. Volume1,076,699
30 Day Avg. Volume2,335,872
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)1.21
P/FCF Ratio5.87
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue0.71
Enterprise Value/Gross Profit0.86
Enterprise Value/Ebitda3.05
Forecast
1Y Price Target
$2.83Price Target Upside26.91% Upside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)0.32
Revenue Forecast (FY)$764.76M
GoodRx Holdings Business Overview & Revenue Model
Company Description
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provide...
How the Company Makes Money
GoodRx primarily earns revenue from its prescription discount and affordability offerings. When a consumer uses a GoodRx coupon/discount at a pharmacy, the transaction is typically processed through a pharmacy benefit manager (PBM) or similar pres...
GoodRx Holdings Key Performance Indicators (KPIs)
Any
Monthly Active Consumers
Shows the number of unique users engaging with the platform each month, highlighting user retention, platform popularity, and potential for monetization.
Shows the number of unique users engaging with the platform each month, highlighting user retention, platform popularity, and potential for monetization.
Data provided by:
The Fly
The FlyGoodRx Holdings Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Neutral
The call presented a mixed but strategically coherent picture: GoodRx demonstrated strong growth and momentum in its Pharma Direct business, meaningful platform scale (including a notable share of Wegovy pill self-pay fills), e-commerce expansion (tripled retail footprint, 83% QoQ order volume growth), and maintained positive adjusted EBITDA and cash reserves. However, the company is navigating material near-term headwinds in its legacy prescription transactions business—driven by lower unit economics, a 6% decline in prescription transactions revenue, a 14% drop in monthly active consumers, one-time partner impacts (~$35M–$40M), and guidance that implies revenue and EBITDA declines in 2026. Management framed 2026 as a transition year in which it will accept near-term pressure to invest in Pharma Direct, subscriptions, and longer-term durability. Given the balance of meaningful growth in strategic areas against tangible near-term financial and volume headwinds, the overall tone is balanced and transitional rather than clearly positive or negative.Positive Updates
Full-Year Revenue and EBITDA Stability
Full-year 2025 revenue of $796.9M (up 1% year-over-year) and full-year Adjusted EBITDA of $270.5M (up 4% year-over-year), with Q4 revenue of $194.8M and Q4 Adjusted EBITDA of $65M; 2025 results were in line with guidance and Adjusted EBITDA was just above midpoint.
Negative Updates
Decline in Prescription Transactions Revenue
Prescription transactions revenue declined 6% year-over-year to $544M in 2025; management expects continued pressure on prescription transaction revenue in 2026 driven by strategic trade-offs and lapping impacts.
Read all updates
Q4-2025 Updates
Positive
Negative
Full-Year Revenue and EBITDA Stability
Full-year 2025 revenue of $796.9M (up 1% year-over-year) and full-year Adjusted EBITDA of $270.5M (up 4% year-over-year), with Q4 revenue of $194.8M and Q4 Adjusted EBITDA of $65M; 2025 results were in line with guidance and Adjusted EBITDA was just above midpoint.
Read all positive updates
Company Guidance
GoodRx guided FY2026 revenue of $750–$780 million and Adjusted EBITDA of at least $230 million (versus FY2025 revenue $796.9M and Adjusted EBITDA $270.5M); the company expects Pharma Direct (2025 revenue $151.4M, +41% YoY) to grow at least 30% in 2026 and said it will invest further in Pharma Direct and condition-specific subscriptions (weight‑loss subscriptions launched late 2025 with < $1M exit revenue but rapid acceleration). Management flagged near‑term pressure on prescription transactions revenue (PTR fell 6% YoY to $544M in 2025, with a ~$35–$40M headwind from Rite Aid/one ISP) and a mid‑single‑digit impact to consolidated revenue from reset unit economics, while modeling MACs roughly flat (exit 2025 MAC ~5.3, expected ~5.2) and monthly active consumers (down 14% in 2025) flattening sequentially from Q4‑25 through Q4‑26; Q4 revenue was $194.8M and Q4 Adjusted EBITDA $65M, and the balance sheet ended 2025 with $261.8M cash and ~$80M revolver capacity (2025 buybacks: ~48.9M shares for $217.4M at $4.45 avg).GoodRx Holdings Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
76
Positive
Cash Flow
71
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 796.85M | 792.32M | 750.26M | 766.55M | 745.42M |
| Gross Profit | 654.13M | 744.11M | 683.34M | 701.48M | 698.71M |
| EBITDA | 184.36M | 153.92M | 108.82M | 65.19M | 48.00M |
| Net Income | 30.44M | 16.39M | -8.87M | -32.83M | -25.25M |
Balance Sheet | |||||
| Total Assets | 1.40B | 1.39B | 1.59B | 1.60B | 1.61B |
| Cash, Cash Equivalents and Short-Term Investments | 261.82M | 448.35M | 672.30M | 757.16M | 941.11M |
| Total Debt | 59.54M | 543.39M | 711.07M | 717.02M | 702.33M |
| Total Liabilities | 787.80M | 663.41M | 826.84M | 789.80M | 775.95M |
| Stockholders Equity | 616.26M | 724.66M | 761.96M | 814.83M | 831.68M |
Cash Flow | |||||
| Free Cash Flow | 164.38M | 113.55M | 82.53M | 91.57M | 144.32M |
| Operating Cash Flow | 167.90M | 183.89M | 138.29M | 146.78M | 178.78M |
| Investing Cash Flow | -119.96M | -70.35M | -55.77M | -210.50M | -178.73M |
| Financing Cash Flow | -234.47M | -337.50M | -167.40M | -120.23M | -30.53M |
GoodRx Holdings Technical Analysis
Neutral
2.23
Price Trends
2.18
Positive
2.44
Negative
3.32
Negative
Market Momentum
-0.01
Negative
56.22
Neutral
86.46
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDRX, the sentiment is Neutral. The current price of 2.23 is above the 20-day moving average (MA) of 2.08, above the 50-day MA of 2.18, and below the 200-day MA of 3.32, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 56.22 is Neutral, neither overbought nor oversold. The STOCH value of 86.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GDRX.
GoodRx Holdings Risk Analysis
GoodRx Holdings disclosed 71 risk factors in its most recent earnings report. GoodRx Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GoodRx Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $118.98M | 95.53 | 18.98% | ― | 2.97% | ― | |
67 Neutral | $714.18M | -72.16 | -7.10% | ― | 50.51% | 50.92% | |
62 Neutral | $736.54M | 42.49 | 4.84% | ― | 1.30% | ― | |
56 Neutral | $520.13M | 347.91 | 0.75% | ― | 14.33% | 93.62% | |
52 Neutral | $931.23M | -6.16 | -14.24% | ― | -2.37% | 77.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $91.86M | -0.82 | -35.88% | ― | 4.33% | 50.50% |
* Healthcare Sector Average
GDRX
GoodRx Holdings
2.23
-2.26
-50.33%
CCLD
CareCloud
2.87
1.44
100.70%
TDOC
Teladoc
5.24
-1.90
-26.61%
PHR
Phreesia
8.60
-15.36
-64.11%
AMWL
American Well
5.51
-1.60
-22.50%
OMDA
Omada Health, Inc.
12.46
-10.14
-44.87%
GoodRx Holdings Corporate Events
Executive/Board Changes
GoodRx Reshapes Board After Director Resignation and Reclassification
Neutral
Apr 3, 2026
On March 31, 2026, GoodRx Holdings director Ian T. Clark resigned from the company’s board and its Nominating Governance Committee, with the company noting his departure did not stem from any disagreement over operations, policies or practi...
Executive/Board Changes
GoodRx Chief Accounting Officer Resigns for New Opportunity
Neutral
Mar 27, 2026
On March 24, 2026, GoodRx Holdings, Inc. announced that Chief Accounting Officer Romin Nabiey submitted his resignation, effective April 3, 2026, to pursue other opportunities, in a move that the company said was not related to any disagreement ov...
Executive/Board Changes
GoodRx Awards Performance-Based Bonus to Chief Accounting Officer
Positive
Mar 6, 2026
On March 3, 2026, GoodRx Holdings, Inc.’s board of directors approved a discretionary cash bonus of $72,918 for 2025 performance for Romin Nabiey, the company’s chief accounting officer. The award highlights the board’s recogniti...
Executive/Board Changes
GoodRx Announces Resignation of Board Member Dipanjan Deb
Neutral
Feb 27, 2026
On February 26, 2026, GoodRx Holdings, Inc. disclosed that board member Dipanjan Deb resigned from its Board of Directors, effective the same day. The company reported that Deb’s departure was not due to any disagreement with management or w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.